Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1807 results
July 2020
-
In The NewsPharma’s pandemic response could help attract tech talentNovartis Chief Digital Officer Bertrand Bodson talked to FiercePharma about pharma’s COVID-19 pandemic reputation boost with potential tech hires.
-
Key ReleaseNovartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologiesCompany finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related…
-
Media ReleaseSandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® caseSandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic…
June 2020
-
In The NewsDeveloping drugs during a pandemicNovartis CEO Vas Narasimhan spoke with WIRED’s Steven Levy and shared his perspective on some of the ways forward for the industry and the world.
-
Media ReleaseNovartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively…
-
Media ReleaseNovartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment optionsBasel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for…
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profileEMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and…
-
Media ReleaseNovartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polypsIf approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-…
-
Key ReleaseNovartis Resolves Legacy FCPA InvestigationsBasel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA)…
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosisThe Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from…
-
Featured NewsNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19
Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.
-
Media ReleaseNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago 86% of tech professionals agree: the…
Pagination
- ‹ Previous page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- …
- 151
- › Next page